At March’s online “Racjonalny Inwestor” conference hosted by StockWatch.pl, our CEO, Wojciech Kula, joined a panel discussion on a key question: how do clinical trial strategies affect a biotech company’s investment appeal?
Wojciech shared the stage with experts from Noble Securities, Navigator Capital, and Bioceltix, discussing how strong clinical results and transparent trial execution build investor confidence.
The session, open and free to all investors, took place on October 15 and underscored the message: in today’s market, robust scientific evidence isn’t just a regulatory milestone—it’s a competitive advantage.
Explore why a well-designed, efficiently run clinical program is among the most powerful tools for enhancing market perception and supporting long-term growth. Watch the recording of the panel here (in Polish).
Axcellant is pleased to announce the formation of its Advisory Board - a group of distinguished experts in clinical science,…
The FDA and the European Commission are changing the rules of the game simultaneously. The shift is from a single…
Modern nuclear medicine is a high-tech discipline that requires advanced facilities, infrastructure, qualified staff, and know-how. The reliable supply of radionuclides,…
Copyright @ 2026 Axcellant